scholarly journals Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC‐0853), in Systemic Lupus Erythematosus

2021 ◽  
Author(s):  
David Isenberg ◽  
Richard Furie ◽  
Nicholas S. Jones ◽  
Pascal Guibord ◽  
Joshua Galanter ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Lupus Erythematosus ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Systemic Lupus ◽  
Bruton's Tyrosine Kinase ◽  
Pharmacodynamic Effects

Bruton's tyrosine kinase in systemic lupus erythematosus

2020 ◽  
Vol 87 (6) ◽  
pp. 670-672
Author(s):  
Hsien-Tzung Liao ◽  
Hsiang-Yuen Tung ◽  
Chang-Youh Tsai ◽  
Bor-Luen Chiang ◽  
Chia-Li Yu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Tyrosine Kinase ◽  
Lupus Erythematosus ◽  
Bruton’S Tyrosine Kinase ◽  
Systemic Lupus ◽  
Bruton's Tyrosine Kinase

scholarly journals Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2808-2810 ◽  
Author(s):  
Harriet S. Walter ◽  
Sandrine Jayne ◽  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Franck Morschhauser ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document